Abstract
The relationships between blood glucose, plasma insulin and plasma BTS 67 582 concentrations were studied in a randomised, placebo-controlled, four-way crossover study involving 16 healthy male volunteers aged between 19 and 43 years. Single oral doses of 125, 250 and 500 mg BTS 67 582 were studied. Fasting blood samples were taken pre-dose and half-hourly for 8 h post-dose. Mean peak plasma concentrations of BTS 67 582 were 518, 1076 and 2435 ng ml-1 for doses of 125, 250 and 500 mg, respectively. Mean maximum reductions in blood glucose were 1.13, 1.59 and 1.78 mmol l-1, and mean maximum increases in plasma insulin were 26, 14 and 21 muu ml-1 for the three doses, respectively. Changes in incremental area under the curve (AUC) of blood glucose were correlated with changes in plasma BTS 67 582 AUC. The maximum reduction in blood glucose was correlated with the peak plasma BTS 67 582 concentration. No correlations between plasma insulin and plasma BTS 67 582 concentrations were observed. Anticlockwise hysteresis was evident in concentration-effect curves, but less evident following subtraction of placebo data, and was mainly due to an underlying downward trend in fasted blood glucose levels with time evident under placebo treatment. This suggests that hypoglycaemic effects were related to systemic BTS 67 582 concentrations, suggesting that active metabolites of the drug do not make a major contribution to acute hypoglycaemic effects. A log-linear model described the relationship between blood glucose and plasma BTS 67 582 concentrations for 14 of the 16 volunteers.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bailey C. J. Biguanides and NIDDM. Diabetes Care. 1992 Jun;15(6):755–772. doi: 10.2337/diacare.15.6.755. [DOI] [PubMed] [Google Scholar]
- Bitzén P. O., Melander A., Scherstén B., Wåhlin-Boll E. The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia. Eur J Clin Pharmacol. 1988;35(1):31–37. doi: 10.1007/BF00555504. [DOI] [PubMed] [Google Scholar]
- Chalk J. B., Patterson M., Smith M. T., Eadie M. J. Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. Eur J Clin Pharmacol. 1986;31(2):177–182. doi: 10.1007/BF00606655. [DOI] [PubMed] [Google Scholar]
- Francheteau P., Steimer J. L., Merdjan H., Guerret M., Dubray C. A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J Pharmacokinet Biopharm. 1993 Oct;21(5):489–514. doi: 10.1007/BF01059111. [DOI] [PubMed] [Google Scholar]
- Gonen B., Rubenstein A., Rochman H., Tanega S. P., Horwitz D. L. Haemoglobin A1: An indicator of the metabolic control of diabetic patients. Lancet. 1977 Oct 8;2(8041):734–737. doi: 10.1016/s0140-6736(77)90237-9. [DOI] [PubMed] [Google Scholar]
- Groop L., Tolppanen E. M. Factors influencing beta-cell function and insulin sensitivity in patients with type 2 (non-insulin-dependent) diabetes. Acta Endocrinol (Copenh) 1984 Aug;106(4):505–510. doi: 10.1530/acta.0.1060505. [DOI] [PubMed] [Google Scholar]
- Haupt E., Beyer J., Schöffling K. Pharmakologische Untersuchungen mit Glisocepid und anderen blutzuckersenkenden Sulfonamidderivaten an Stoffwechselgesunden und Diabetikern. Arzneimittelforschung. 1974 Mar;24(0):418–425. [PubMed] [Google Scholar]
- Haupt E., Laube F., Loy H., Schöffling K. Neue Untersuchungen zum Sekundärversagen der Therapie mit blutglucosesenkenden Sulfonamidderivaten. Med Klin. 1977 Sep 23;72(38):1529–1536. [PubMed] [Google Scholar]
- Hermann L. S. Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab. 1979 Sep;5(3):233–245. [PubMed] [Google Scholar]
- Marchetti P., Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet. 1989 Feb;16(2):100–128. doi: 10.2165/00003088-198916020-00004. [DOI] [PubMed] [Google Scholar]
- Meglasson M. D., Wilson J. M., Yu J. H., Robinson D. D., Wyse B. M., de Souza C. J. Antihyperglycemic action of guanidinoalkanoic acids: 3-guanidinopropionic acid ameliorates hyperglycemia in diabetic KKAy and C57BL6Job/ob mice and increases glucose disappearance in rhesus monkeys. J Pharmacol Exp Ther. 1993 Sep;266(3):1454–1462. [PubMed] [Google Scholar]
- Schäfer G. On the mechanism of action of hypoglycemia-producing biguanides. A reevaluation and a molecular theory. Biochem Pharmacol. 1976 Sep 15;25(18):2005–2014. doi: 10.1016/0006-2952(76)90423-8. [DOI] [PubMed] [Google Scholar]